Acute pain in oncology: specific features and treatment options. What is new?

Background: Cancer patients experience acute pain at various the stages of antitumor therapy, which can reduce the patient's commitment to treatment and trust in the doctor, therefore, rapid relief of acute pain is very important. Objective: The aims of the article is to describe the options for acute pain relief in oncology, to characterize the main groups of analgetics, to present data of clinical trials and clinical cases of the use of Tafalgin — the new generation drug from the group of central analgesics. Methods: Analysis of the literature on pain therapy in cancer therapy, and own data within the framework of the multicenter study “Observational program for monitoring the effectiveness and safety of Tafalgin® in real clinical practice — NIKITA”. Results: The classification of acute pain in cancer patients in cancer therapy is proposed, analgesics and the features of their use depending on the intensity of pain are described. The results of Tafalgin use show that in 15 minutes after its subcutaneous administration there was a decrease in the intensity of pain by 59.6 %. The duration of analgesia reached 9.35 ± 6.3 hours. An acceptable level of pain relief was achieved in 84 % of patients. 19 mild and moderate adverse events were detected in 15 patients. Conclusion: Acute pain in cancer patients continues to be a problem, despite the large number of analgesics, so the introduction into clinical practice of a new effective analgesic Tafalgin might ensure pain control.